Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 4/20 | 0.65 |
| ▸ | JAK2 | O60674 | 10/20 | 0.56 |
| ▸ | JAK3 | P52333 | 5/20 | 0.55 |
| ▸ | JAK1 | P23458 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962934 | 0.87 | SMG1 (0.68) | SMG1JAK2JAK3JAK1KCNH2 | |
| SCHEMBL12921700 | 0.85 | JAK2 (0.56) | SMG1JAK2JAK3JAK1CAMK2D | |
| SCHEMBL1667134 | 0.84 | JAK2 (0.77) | SMG1JAK2JAK3JAK1CAMK2D | |
| SCHEMBL30051959 | 0.84 | JAK2 (0.77) | SMG1JAK2JAK3JAK1CAMK2D | |
| SCHEMBL12921641 | 0.83 | JAK2 (0.55) | SMG1JAK2JAK3JAK1CAMK2D | |
| SCHEMBL1670895 | 0.81 | SMG1 (0.51) | SMG1JAK2JAK3JAK1KCNH2 | |
| SCHEMBL1670901 | 0.81 | SMG1 (0.51) | SMG1JAK2JAK3JAK1KCNH2 | |
| SCHEMBL12921615 | 0.80 | SMG1 (0.50) | SMG1JAK2JAK3JAK1KCNH2 | |
| SCHEMBL1670898 | 0.80 | SMG1 (0.50) | SMG1JAK2JAK3JAK1KCNH2 | |
| SCHEMBL12275374 | 0.79 | SMG1 (0.57) | SMG1JAK2JAK3JAK1CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791697-A | Amino-pyrimidine compounds as inhibitors of TBKL and/or IKK epsilon | MYREXIS INC | 2012-11-21 | — | — | CN | claimed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | claimed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | claimed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-28 | — | — | US | disclosed |
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-28 | — | — | US | disclosed |
| US-8318929-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-8318929-B2 | 4-aryl-2-anilino-pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| CN-102791697-A | Amino-pyrimidine compounds as inhibitors of TBKL and/or IKK epsilon | MYREXIS INC | 2012-11-21 | — | — | CN | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053379-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | SMG1 2205/4885JAK2 372/4885JAK3 462/4885 |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | SMG1 59/4885JAK2 1160/4885JAK3 476/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | SMG1 305/4885JAK2 458/4885JAK3 197/4885 |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | SMG1 2205/4885JAK2 372/4885JAK3 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.